Literature DB >> 30625372

STRONG-D: Strength training regimen for normal weight diabetics: Rationale and design.

Lida Faroqi1, Saniya Bonde2, Daniella Tatianna Goni2, Chi Wai Wong2, Myo Wong2, Khalil Walai2, Saron Araya2, Sayed Azamey2, Gabriella Schreiner2, Monica Bandy2, Sonia Sunita Raghuram2, Anuva Mittal2, Aishee Mukherji2, Tenzin Wangdak2, Ruth Talamoa2, Katherine Vera2, Carla Nacif-Coelho2, Leah Groppo Cde3, Mary Christensen4, Neil Johannsen3, Francois Haddad5, Minal Moharir2, Latha Palaniappan2.   

Abstract

BACKGROUND: Currently, there is a lack of data on effective lifestyle recommendations for normal-weight diabetics (NWD), who can represent up to 1 in 5 individuals with Type II Diabetes Mellitus (T2DM). NWD is especially prevalent in Asian populations and the elderly. Specific exercise treatment recommendations are needed for patients with normal-weight diabetes (NWD), as those in this category face higher mortality rates than overweight and obese diabetics. Standard T2DM treatment recommends aerobic training; however, performing aerobic training alone may not be appropriate for NWD and strength training may be a more effective treatment recommendation.
OBJECTIVE: While it is known that strength and aerobic training are beneficial in obese diabetics, there is currently insufficient evidence to recommend this regimen in NWD. The Strength Training Regimen for Normal Weight Diabetics (STRONG-D) study aims to determine the best exercise regimen for NWD and address the current lack of appropriate physical activity recommendations for this population. The primary goal of this study is to determine whether strength training aids glycemic control better than aerobic training in NWD. STUDY
DESIGN: STRONG-D is a three-arm randomized controlled trial designed to compare the clinical effectiveness of structured strength training only, aerobic training only, and combination (strength + aerobic) training sessions, modeled after the intervention in the Health Benefits of Aerobic and Resistance Training in T2DM patients (HART-D) study. Potential participants meeting eligibility criteria of HbA1c values of 6.5% to 13.0% and BMI of 18.5 kg/m2 to 25 kg/m2 will be enrolled. After randomization, participants will begin a 9-month exercise intervention. The primary outcomes will be HbA1c levels. The secondary endpoints will include physical fitness, body composition measured by Dual X-Ray Absorptiometry (DXA) scans, and leg strength and endurance measured by Biodex testing. Initial follow-up visits will occur at 3 months, 6 months, and 9 months. To determine the long-term effects of the exercise intervention, passive follow-up will continue via electronic health records (EHR) until a 24-month follow-up visit. A total of 282 participants will be randomized into the three study arms determine the clinically significant differences between strength-only, aerobic-only and combination regimens.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30625372     DOI: 10.1016/j.cct.2019.01.005

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  2 in total

1.  Incremental value of diastolic stress test in identifying subclinical heart failure in patients with diabetes mellitus.

Authors:  Tomoko Nishi; Yukari Kobayashi; Jeffrey W Christle; Nicholas Cauwenberghs; Kalyani Boralkar; Kegan Moneghetti; Myriam Amsallem; Kristofer Hedman; Kévin Contrepois; Jonathan Myers; Kenneth W Mahaffey; Ingela Schnittger; Tatiana Kuznetsova; Latha Palaniappan; Francois Haddad
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-08-01       Impact factor: 6.875

2.  The digital biomarker discovery pipeline: An open-source software platform for the development of digital biomarkers using mHealth and wearables data.

Authors:  Brinnae Bent; Ke Wang; Emilia Grzesiak; Chentian Jiang; Yuankai Qi; Yihang Jiang; Peter Cho; Kyle Zingler; Felix Ikponmwosa Ogbeide; Arthur Zhao; Ryan Runge; Ida Sim; Jessilyn Dunn
Journal:  J Clin Transl Sci       Date:  2020-07-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.